Chemically modified PAL has been used as a therapy for phenylketonuria (PKU) [9, 16], which is an inborn disorder of phenylalanine metabolism caused by deficiency of phenylalanine hydroxylase (PAH), causing cognitive development loss and mental retardation as a result of hyperphenylalaninemia [17, 18]. This evidence concerns the gene PAH and phenylketonuria.